SG小鸭子
2021-12-22
Grr
BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":691617393,"tweetId":"691617393","gmtCreate":1640183345016,"gmtModify":1640183716416,"author":{"id":3561283969704258,"idStr":"3561283969704258","authorId":3561283969704258,"authorIdStr":"3561283969704258","name":"SG小鸭子","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":22,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Grr</p></body></html>","htmlText":"<html><head></head><body><p>Grr</p></body></html>","text":"Grr","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691617393","repostId":1165830356,"repostType":4,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b> has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.</p>\n<ul>\n <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>\n <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>\n <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.</li>\n <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>\n <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>\n <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>\n <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>\n <li><b>Price Action:</b> BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 22:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b> has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.</p>\n<ul>\n <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>\n <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>\n <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.</li>\n <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>\n <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>\n <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>\n <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>\n <li><b>Price Action:</b> BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":454,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/691617393"}
精彩评论